NCT03597412View on ClinicalTrials.gov

Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DM

PHASE4CompletedINTERVENTIONAL
Enrollment

236

Participants

Timeline

Start Date

October 17, 2018

Primary Completion Date

August 12, 2020

Study Completion Date

August 12, 2020

Conditions
Atherosclerotic Cardiovascular DiseaseType 2 Diabetes Mellitus
Interventions
DRUG

Rosuvamibe

Rosuvastatin 10mg/Ezetimibe 10mg

DRUG

Monorova

Rosuvastatin 20mg

Trial Locations (1)

Unknown

Kangbuk Samsung Hospital, Seoul

All Listed Sponsors
lead

Yuhan Corporation

INDUSTRY

NCT03597412 - Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DM | Biotech Hunter | Biotech Hunter